Regulation - Pharmaceutical, Amgen

Filter

Current filters:

PharmaceuticalAmgen

Popular Filters

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan

29-08-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has filed an application for approval in Japan to manufacture…

AmgenAsia-PacificDaiichi SankyoOncologyPharmaceuticalPraliaRanmarkRegulation

European Commission OK for Lonquex

09-08-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA|), the world's leading generics drugmaker, says…

AmgenEuropeLonquexOncologyPharmaceuticalRegulationTeva Pharmaceutical Industries

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

Daiichi Sankyo files denosumab in Japan for osteoporosis

26-03-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) revealed on Friday that it has filed for approval in Japan…

AmgenAnti-Arthritics/RheumaticsAsia-PacificDaiichi SankyodenosumabPharmaceuticalRegulation

Amgen fails to get FDA advisory backing for extended use of Xgeva

09-02-2012

The world’s largest independent biotech firm, Amgen (Nasdaq: AMGN), has failed to convince a Food…

AmgenBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationXgeva

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

FDA eases REMS requirements for Amgen’s Nplate and GSK’s Promacta

07-12-2011

The US Food and Drug Administration says that an agency initiated review of the current information has…

AmgenBiotechnologyGlaxoSmithKlineNorth AmericaNplatePharmaceuticalPromactaRare diseasesRegulation

More cancer and HIV drugs added to Australian PBS

07-12-2011

More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits…

AmgenAnti-viralsAsia-PacificGilead SciencesOncologyPharmaceuticalPrezistaPricingRegulationXgeva

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis

25-11-2011

In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Amgen’s Prolia increases bone mineral density over eight; new indications approved

20-09-2011

The world’s largest biotechnology firm, USA-based Amgen (Nasdaq: AMGN) says that new long-term data…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlinePharmaceuticalProliaRegulationResearchXgeva

UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix

06-09-2011

In new draft guidance issued this week, UK drug watchdog the National Institute for Health and Clinical…

AmgenAvastinErbituxEuropeMerck KGaAOncologyPharmaceuticalPricingRegulationRocheVectibix

Back to top